Literature DB >> 1736567

The effects of intravenous infusions of selective adenosine A1-receptor and A2-receptor agonists on myocardial reperfusion injury.

E D Norton1, E K Jackson, M B Turner, R Virmani, M B Forman.   

Abstract

To determine the efficacy of very low doses of adenosine on myocardial reperfusion injury and whether its effect is receptor mediated, 78 rabbits underwent 30 minutes of left circumflex artery occlusion and 48 hours of reperfusion. Animals were randomly assigned to receive one of three doses of adenosine, cyclopentyladenosine (a selective A1-receptor agonist), or CGS 21680C (a selective A2-receptor agonist). The drugs were infused for 65 minutes beginning 5 minutes before reperfusion. A significant reduction in histologically determined infarct size was noted with all three doses of adenosine, intermediate and low doses of the A1-receptor agonist (cyclopentyladenosine), and high and intermediate doses of the A2-receptor agonist (CGS 21680C). Furthermore, all three adenosine receptor agonists afforded similar degrees of protection. Results of this study demonstrate that intravenous infusions of very low doses of adenosine significantly enhance myocardial salvage and this protection is receptor mediated. Furthermore, the administration of the A1-receptor agonist would be clinically appealing, since it would avoid the potential side effects associated with activation of A2 receptors.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1736567     DOI: 10.1016/0002-8703(92)90643-a

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  21 in total

Review 1.  Adenosine receptors and reperfusion injury of the heart.

Authors:  John P Headrick; Robert D Lasley
Journal:  Handb Exp Pharmacol       Date:  2009

2.  ADORA2b Signaling in Cardioprotection.

Authors:  Jennifer Gile; Tobias Eckle
Journal:  J Nat Sci       Date:  2016

3.  Adenosine A₂A and A₂B receptors are both required for adenosine A₁ receptor-mediated cardioprotection.

Authors:  Enbo Zhan; Victoria J McIntosh; Robert D Lasley
Journal:  Am J Physiol Heart Circ Physiol       Date:  2011-07-08       Impact factor: 4.733

Review 4.  Targeting of adenosine receptors in ischemia-reperfusion injury.

Authors:  Victor E Laubach; Brent A French; Mark D Okusa
Journal:  Expert Opin Ther Targets       Date:  2010-11-29       Impact factor: 6.902

5.  Adenosine A2A and A2B receptors work in concert to induce a strong protection against reperfusion injury in rat hearts.

Authors:  Jinkun Xi; Rachel McIntosh; Xiangjun Shen; SungRyul Lee; Guillaume Chanoit; Hugh Criswell; David A Zvara; Zhelong Xu
Journal:  J Mol Cell Cardiol       Date:  2009-08-18       Impact factor: 5.000

Review 6.  Adenosine and cardioprotection during reperfusion--an overview.

Authors:  Martín Donato; Ricardo J Gelpi
Journal:  Mol Cell Biochem       Date:  2003-09       Impact factor: 3.396

7.  Left ventricular function and cardiovascular events following adjuvant therapy with adenosine in acute myocardial infarction treated with thrombolysis, results of the ATTenuation by Adenosine of Cardiac Complications (ATTACC) study.

Authors:  Miguel Quintana; Paul Hjemdahl; Alf Sollevi; Thomas Kahan; Magnus Edner; Nina Rehnqvist; Eva Swahn; Ann-Catrin Kjerr; Per Näsman
Journal:  Eur J Clin Pharmacol       Date:  2003-03-18       Impact factor: 2.953

8.  A Food and Drug Administration-Approved Antiviral Agent that Inhibits Adenylyl Cyclase Type 5 Protects the Ischemic Heart Even When Administered after Reperfusion.

Authors:  Claudio A Bravo; Dorothy E Vatner; Ronald Pachon; Jie Zhang; Stephen F Vatner
Journal:  J Pharmacol Exp Ther       Date:  2016-03-03       Impact factor: 4.030

9.  Reduction in myocardial infarct size at 48 hours after brief intravenous infusion of ATL-146e, a highly selective adenosine A2A receptor agonist.

Authors:  Rajan A G Patel; David K Glover; Alexis Broisat; Hasan K Kabul; Mirta Ruiz; N Craig Goodman; Christopher M Kramer; Denis J Meerdink; Joel Linden; George A Beller
Journal:  Am J Physiol Heart Circ Physiol       Date:  2009-06-05       Impact factor: 4.733

Review 10.  Signalling pathways and mechanisms of protection in pre- and postconditioning: historical perspective and lessons for the future.

Authors:  Michael V Cohen; James M Downey
Journal:  Br J Pharmacol       Date:  2014-11-24       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.